Sosei Assigns AD 923 Assets to Pharmasol
09-Oct-2009
- United Kingdom
The AD 923 development programme had previously entered Phase III clinical trials in Europe. However, due to the changes in regulatory environment, restructuring of Sosei R&D business operation, the programme had been halted.
Based on the present agreement Sosei R&D will receive payments from Pharmasol based on revenues arising from the commercialization of these assigned assets.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.